Application US20170191129

BIOMARKER SIGNATURE METHOD, AND APPARATUS AND KITS THEREOF
[+] Show Details

US20170191129

1-142. (canceled) (0)

143. A method for inhibiting the development or progression of inSIRS or ipSIRS in a subject, the method comprising: (1) providing an indicator used in assessing a likelihood of the presence of inSIRS or ipSIRS in the subject; and (2) exposing the subject to a treatment regimen for treating inSIRS based on the indicator indicating a likely presence of inSIRS in the subject, or exposing the subject to a treatment regimen for treating ipSIRS based on the indicator indicating a likely presence of ipSIRS in the subject, wherein the indicator is determined by an indicator-determining method, the indicator-determining method comprising: (a) determining at least one pair of biomarker values, each biomarker value being a value measured or derived for a corresponding immune system biomarker in a sample taken from the subject; (b) determining at least one derived biomarker value using the at least one pair of biomarker values, the derived biomarker value being indicative of a ratio of concentrations of a corresponding pair of immune system biomarkers in the sample; and (c) determining the indicator based on the at least one derived biomarker value, (4) (1)

wherein the at least one pair of biomarker values comprises a first pair of biomarker values comprising first and second biomarker values corresponding to first and second immune system biomarkers, respectively, wherein the first immune system biomarker represents a polynucleotide expression product of the PLA2G7 gene and wherein the second immune system biomarker represents a polynucleotide expression product of the PLAC8 gene.

144. The method of claim 143, wherein the at least one pair of biomarker values further comprises a second pair of biomarker values comprising third and fourth biomarker values corresponding to third and fourth immune system biomarkers, respectively, wherein the third immune system biomarker represents a polynucleotide expression product of the CEACAM4 gene and wherein the fourth immune system biomarker represents a polynucleotide expression product of the LAMP1 gene. (1) (0)

146. The method of claim 143, wherein the sample is a blood sample. (0)

147. The method of claim 143, wherein the sample comprises leukocytes. (0)

148. The method of claim 143, wherein the sample comprises peripheral blood mononuclear cells. (0)

149. A method for inhibiting the development or progression of inSIRS or ipSIRS in a subject, the method comprising: (1) providing an indicator used in assessing a likelihood of the presence of inSIRS or ipSIRS in the subject; and (2) exposing the subject to a treatment regimen for treating inSIRS based on the indicator indicating a likely presence of inSIRS in the subject, or exposing the subject to a treatment regimen for treating ipSIRS based on the indicator indicating a likely presence of ipSIRS in the subject, wherein the indicator is determined by an indicator-determining method, the indicator-determining method comprising: (a) determining at least two pairs of biomarker values comprising a first pair of biomarker values and a second pair of biomarker values, each biomarker value being a value measured or derived for a corresponding immune system biomarker in a sample taken from the subject; (b) determining a first derived biomarker value using the first pair of biomarker values, the first derived biomarker value being indicative of a ratio of concentrations of a corresponding first pair of immune system biomarkers in the sample; (c) determining a second derived biomarker value using the second pair of biomarker values, the second derived biomarker value being indicative of a ratio of concentrations of a corresponding second pair of immune system biomarkers in the sample; and (d) determining the indicator based on a combination of at least the first derived biomarker value and the second derived biomarker value, (5) (2)

wherein one of the first pair of immune system biomarkers represents a polynucleotide expression product of the PLA2G7 gene and wherein the other of first pair of immune system biomarkers represents a polynucleotide expression product of the PLAC8 gene, and

wherein one of the second pair of immune system biomarkers represents a polynucleotide expression product of the CEACAM4 gene and wherein the other of the second pair of immune system biomarkers represents a polynucleotide expression product of the LAMP1 gene.

150. The method of claim 149, wherein the first and second derived biomarker values are combined using a combining function, the combining function being at least one of: (0) (11)

a) an additive model;

b) a linear model;

c) a support vector machine;

d) a neural network model;

e) a random forest model;

f) a regression model;

g) a genetic algorithm;

h) an annealing algorithm;

i) a weighted sum;

j) a nearest neighbor model; and,

k) a probabilistic model.

151. A method according to claim 149, wherein the indicator-determining method comprises: (1) (2)

a) quantifying polynucleotide expression products by: i) amplifying at least some polynucleotide expression products in the sample; and,

ii) determining an amplification amount representing a degree of amplification required to obtain a defined level of each of a pair of polynucleotide expression products; and,

b) determining the indicator by determining a difference between the amplification amounts.

152. A method according to claim 151, wherein the amplification amount is at least one of: (0) (5)

c) a cycle time;

d) a number of cycles;

e) a cycle threshold;

f) an amplification time; and,

g) relative to an amplification amount of another amplified product.

153. The method of claim 149, wherein the sample is a blood sample. (0)

154. The method of claim 149, wherein the sample comprises leukocytes. (0)

155. The method of claim 149, wherein the sample comprises peripheral blood mononuclear cells. (0)

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Application US20170191129

BIOMARKER SIGNATURE METHOD, AND APPARATUS AND KITS THEREOF

Patent Matrix® Search